UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1264-7
Program Prior Authorization/Notification
Medication Arikayce® (amikacin liposome inhalation suspension)
P&T Approval Date 11/2018, 11/2019, 11/2020, 11/2021, 11/2022, 11/2023, 11/2024
Effective Date 2/1/2025
1. Background:
Arikayce is an aminoglycoside antibacterial indicated in adults who have limited or no
alternative treatment options, for the treatment of Mycobacterium avium complex (MAC) lung
disease as part of a combination antibacterial drug regimen in patients who do not achieve
negative sputum cultures after a minimum of 6 consecutive months of a multidrug background
regimen therapy. As only limited clinical safety and effectiveness data for Arikayce are
currently available, reserve Arikayce for use in adults who have limited or no alternative
treatment options. This drug is indicated for use in a limited and specific population of
patients.1
This indication is approved under accelerated approval based on achieving sputum culture
conversion (defined as 3 consecutive negative monthly sputum cultures) by Month 6. Clinical
benefit has not yet been established.1
Limitation of Use:
Arikayce has only been studied in patients with refractory MAC lung disease defined as
patients who did not achieve negative sputum cultures after a minimum of 6 consecutive
months of a multidrug background regimen therapy. The use of Arikayce is not recommended
for patients with non-refractory MAC lung disease.1
2. Coverage Criteriaa:
A. Initial Authorization
1. Arikayce will be approved based on all of the following criteria:
a. Diagnosis of Mycobacterium avium complex (MAC) lung disease
-AND-
b. Patient has not achieved negative sputum cultures after a minimum of 6 consecutive
months of a multidrug background regimen therapy (e.g. macrolide, rifampin, &
ethambutol) within the past 12 months
-AND-
c. Patient has limited or no alternative treatment options
-AND-
© 2024 UnitedHealthcare Services, Inc.
1
d. Used as part of a combination antibacterial drug regimen
Authorization will be issued for 6 months.
B. Reauthorization
1. Arikayce will be approved based on the following criterion:
a. Patient has achieved negative sputum cultures
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits may be in place.
• Medical Necessity may be in place.
4. References:
1. Arikayce [packae insert]. Bridgewater, NJ: Insmed; February 2023
Program Prior Authorization/Notification – Arikayce® (amikacin liposome
inhalation suspension)
Change Control
11/2018 New program
11/2019 Annual review. No changes.
11/2020 Annual review. References updated.
11/2021 Annual review. Updated clinical criteria to reflect labeled indication.
Updated reference.
11/2022 Annual review with no change to clinical criteria. Added state mandate
footnote.
11/2023 Annual review with no change to clinical criteria. Updated reference.
11/2024 Annual review with no change to clinical criteria.
© 2024 UnitedHealthcare Services, Inc.
2